Accueil>>Signaling Pathways>> Chromatin/Epigenetics>> Epigenetic Reader Domain>>Menin-MLL inhibitor 20

Menin-MLL inhibitor 20

Catalog No.GC63538

L'inhibiteur de ménine-MLL 20 est un inhibiteur irréversible de l'interaction ménine-MLL avec des activités antitumorales (WO2020142557A1, intermédiaire 6).

Products are for research use only. Not for human use. We do not sell to patients.

Menin-MLL inhibitor 20 Chemical Structure

Cas No.: 2448173-47-3

Taille Prix Stock Qté
5 mg
153,00 $US
En stock
10 mg
252,00 $US
En stock
25 mg
504,00 $US
En stock
50 mg
819,00 $US
En stock
100 mg
1 305,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, compound 6)[1].

The Histone-lysine N-methyltransferase 2 (KMT2) family of proteins, which currently consists of at least 5 members, methylate ly sine 4 on the histone H3 tails at important regulatory regions in the genome and thereby impart crucial functions through the modulation of chromatin structures and DNA accessibility. These enzymes are known to play an important role in the regulation of gene expression during early development and hematopoiesis. The human KMT2 family was initially named the mixed-lineage leukaemia (MLL) family, owing to the role of the first-found member in this disease[1].

[1]. Thomas Butler, et al. Irreversible inhibitors of menin-mll interaction. WO2020142557A1.

Avis

Review for Menin-MLL inhibitor 20

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Menin-MLL inhibitor 20

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.